C

Corbus Pharmaceuticals Holdings
D

CRBP

8.20000
USD
-0.09
(-1.09%)
مغلق
حجم التداول
6,251
الربح لكل سهم
-5
العائد الربحي
-
P/E
-2
حجم السوق
99,871,752
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.350
    (-1.73%)
    19.940 USD
    A
    AKTX
    -0.05610
    (-5.55%)
    0.95390 USD
    C
    CARA
    -0.02000
    (-0.39%)
    5.05000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    T
    TLRY
    0.06110
    (7.03%)
    0.93000 USD
    المزيد
الأخبار
المقالات

العنوان: Corbus Pharmaceuticals Holdings

القطاع: Healthcare
الصناعة: Biotechnology
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.